The AAAS Annual Meeting is a premier scientific conference for researchers, educators, policymakers, and science enthusiasts to explore cutting-edge advancements in science and technology. Designed for a global audience, it encourages interdisciplinary collaboration and knowledge exchange.
The AAAS Annual Meeting stands as a beacon for the world's scientific community, providing a platform for the dissemination of pioneering research and fostering discussions on the crucial intersection of science and society. Attendees can expect rich programming including lightning talks, plenary sessions, and networking events aimed at sparking innovation and collaboration across disciplines. With a diverse array of speakers and topics, the meeting illuminates paths towards addressing global scientific challenges.
What you will learn
Innovative scientific research and methodologies.
Interdisciplinary approaches to problem-solving.
Impact of science on policy and society.
Latest advancements in technology and research.
Networking opportunities with global science leaders.
Want to exhibit at this event?
MarketScale can act as a third-party concierge, helping you request exhibitor packages, pricing, and booth availability. No cold calls, no commitment.
Key Highlights
• Keynote addresses from leading scientists.
• Sessions on science policy and communication.
• Workshops on scientific innovation.
• Panel discussions with cross-disciplinary experts.
Frequently asked questions
Topics & tracks
MarketScale platform
Onsite Video Booking
Capture every session. Not just the keynote.
Book an onsite crew or capture it yourself. MarketScale turns your sessions, speakers, and hallway conversations into content that outlasts the event.
Book summit capture →sciences articles
Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade
More than $300 billion in branded pharmaceutical revenue faces patent expiration by 2030. Big Pharma cannot replace it through internal R&D alone. The result is the most aggressive acquisition cycle since before the pandemic, and it is reshaping how the entire life sciences supply chain does business.
Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic
Quotient Sciences initiates what it calls the first Phase I trial of an AI-designed oral drug formulation, approved by the UK's MHRA.
Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic
Quotient Sciences has initiated a Phase I study of an AI-designed oral formulation, cleared by the MHRA—marking a concrete shift from AI experimentation to clin
MarketScale
MarketScale helps B2B teams cover events like this and turn them into content their market reads. Want to talk through what that looks like?